BMRN
Biomarin Pharmaceutical Inc
60.30$
-1.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.8% | -24.9% | -20.4% | -0.7% | 1.4% | 2.8% | 4.6% | 16.5% | 8.4% | 6.6% | 20.1% | 25.7% | |
| 7.6% | 5.3% | 8.7% | 6.7% | 6.4% | 6.2% | 5.7% | 5.9% | 4.9% | 4.3% | 3.4% | 2.5% | |
| 11.8% | 12.5% | 12.1% | 10.7% | 10.0% | 9.4% | 10.2% | 10.7% | 9.4% | 8.6% | 7.1% | 5.6% | |
| 3.6% | -15.9% | 41.7% | 6.0% | 1.3% | 3.3% | -36.1% | 10.0% | 1.4% | – | – | – | |
| -4.0% | 5.2% | -14.4% | -7.2% | -3.3% | -5.9% | -12.1% | 3.6% | -4.6% | -13.9% | -7.6% | -3.4% | |
| 15.9% | 25.6% | 13.3% | 15.2% | 9.7% | 8.5% | 7.4% | 6.5% | 5.8% | 4.4% | 3.4% | 3.2% | |
| 26.0% | -132.6% | -43.3% | -23.3% | 17.7% | -1.8% | -2.9% | -19.8% | -1.0% | -4.6% | 4.8% | -12.9% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | 0.6% | 3.9% | 0.2% | 0.7% | – | – | – | |
| -1.0% | -2.6% | -5.3% | -2.6% | -2.4% | -2.5% | -2.7% | -2.5% | -2.6% | -3.2% | -2.7% | – | |
| -0.1% | 0.0% | 43.1% | 36.7% | -25.1% | -0.3% | 11.3% | -0.2% | -0.1% | 0.0% | -17.3% | 0.0% | |
| 24.8% | 104.3% | 65.1% | 38.6% | -26.0% | -4.4% | 9.7% | 0.0% | -0.9% | -0.8% | -18.4% | -1.3% | |
| 40.9% | -53.8% | 1.0% | 14.4% | -7.0% | -3.3% | 11.4% | -3.4% | 6.5% | 1.3% | 6.6% | 11.5% | |
| -25.7% | -50.5% | -33.7% | -15.8% | -8.3% | -5.7% | -2.8% | 10.0% | 2.6% | 2.1% | 16.7% | 22.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.